Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report third quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the live webcast link will be provided and an archived webcast will be available for at least 30 days in the Investors section of the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) said management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025 at 4:40 p.m. ET. The company is a clinical-stage biopharmaceutical developer focused on therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. A live webcast will be available via the company Investors page and archived for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference with a fireside chat on September 2 at 3:15 p.m. ET, and the Cantor Global Healthcare Conference 2025 with a fireside chat on September 5 at 9:10 a.m. ET. Both presentations will be available via webcast on the company's website for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q2 2025 financial results and business updates for its Alzheimer's disease therapeutics development. The company maintains a strong cash position of $166.2 million as of June 30, 2025, expected to fund operations into early 2027.
Key developments include operational innovations in the ALTITUDE-AD Phase 2 trial of sabirnetug, achieving 40% reduction in screening costs through innovative biomarker testing. The company also announced a collaboration with JCR Pharmaceuticals to develop Enhanced Brain Delivery (EBD™) therapy, combining sabirnetug with JCR's blood-brain barrier-penetrating technology.
Financial results show R&D expenses increased to $37.1 million from $19.5 million year-over-year, while net loss widened to $41.0 million from $20.5 million. Topline results from ALTITUDE-AD are expected in late 2026.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its second quarter 2025 financial results announcement for August 12, 2025.
The company will host a conference call and audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register at least one day in advance to receive dial-in information. The webcast will be archived for 30 days on Acumen's investor relations website.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented significant findings at the Alzheimer's Association International Conference (AAIC) 2025 regarding their Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease. The company reported a 40% reduction in clinical trial screening costs through an innovative pTau217 blood-based screening assay.
The two-step screening process demonstrated high efficiency, with 48% of participants meeting initial pTau217 thresholds and 81% of those subsequently confirming amyloid positivity. Additionally, nonclinical studies revealed sabirnetug's superior selectivity for amyloid beta oligomers (AβOs), achieving 8,750-fold selectivity for Aβ1-42 stabilized oligomers over Aβ1-40 monomers, outperforming other tested antibodies including lecanemab and aducanumab.
Acumen Pharmaceuticals (NASDAQ: ABOS) has entered a strategic collaboration with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease. The partnership combines Acumen's amyloid beta oligomer-selective antibody expertise with JCR's blood-brain barrier penetrating technology (J-Brain Cargo®).
The collaboration follows over a year of feasibility work and aims to develop up to two candidates, with preclinical data expected in early 2026. Acumen's lead program, sabirnetug, has shown promising results in Phase 1 trials and is currently in a Phase 2 ALTITUDE-AD trial with 542 patients, with topline results expected in late 2026.
Under the agreement, JCR will receive an upfront payment, potential option payment, milestone payments, and single-digit percentage royalties on future sales.
Acumen Pharmaceuticals (NASDAQ: ABOS) will present two studies at the Alzheimer's Association International Conference (AAIC® 2025) in Toronto from July 27-31, 2025. The first presentation will analyze cost savings from using pTau217 as a screening tool in their Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's disease. The second study will examine sabirnetug's selectivity for Aβ oligomers compared to other treatments.
The presentations will be delivered as posters on July 28 and 29, featuring findings that demonstrate the company's progress in trial design efficiency and the drug's targeted therapeutic approach. Dr. Todd Feaster and Dr. Erika N. Cline will present the respective studies, focusing on biomarker-driven screening and drug selectivity analysis.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the upcoming Bank of America Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Acumen's website at www.acumenpharm.com, where the recording will remain available for 90 days.